Havrilesky LJ, Lim S, Ehrisman JA, et al. - Researchers performed a survey among women with ovarian cancer to measure their preferences about risks, side effects, expenses as well as benefits provided by maintenance therapy (MT) with a poly ADP ribose polymerase (PARP) inhibitor. The survey was completed by 95 eligible participants, with mean age of 62 years. Recurrence was experienced by 48% of patients, and 17% were ever-PARP inhibitor users. The most highly ranked were overall survival (OS)(average importance weight 24.5 out of 100) and monthly costs (24.6), as per participants' preferences. Next valued were risk of death from myelodysplastic syndrome/acute myelogenous leukemia (17.9), nausea (14.7), progression-free survival (PFS) (10.5) and fatigue (7.8). Based on the findings, it was obvious that these patients were most motivated by gains in OS when considering MT. To endure mild side effects of treatment, women expected at least 3–4 months of PFS benefit.